Psychiatric NP Scope of Practice for ADHD in Georgia

You’ve seen the demand: ADHD patient inquiries flooding your inbox, long waitlists in your area, and telehealth platforms promising steady patient flow. But before you start treating ADHD via video visits, you’re probably asking: Can I legally prescribe Adderall or Ritalin through telehealth? What about across state lines? Do the rules differ for NPs versus psychiatrists?

The short answer: Yes, you can prescribe ADHD medications via telehealth right now — but the rules are complex, state-dependent, and evolving. As of early 2026, federal flexibilities allow prescribing Schedule II stimulants without an in-person exam through the end of the year, but permanent regulations are coming. And each state adds its own layer of requirements around licensure, scope of practice, and PDMP checks.

This guide cuts through the confusion. Whether you’re a psychiatrist, PMHNP, or PA considering telehealth ADHD care, here’s what you need to know about current federal rules, state-by-state differences in our six priority markets (California, Texas, Florida, New York, Pennsylvania, and Illinois), and what’s changing in 2026–2027.

The Federal Picture: Temporary Flexibilities Through 2026

The Ryan Haight Act (2008) normally requires an in-person medical evaluation before prescribing any controlled substance — including ADHD stimulants. Pre-COVID, that meant you couldn’t start a patient on Adderall after just a video consult unless narrow exceptions applied (which, practically speaking, didn’t exist for most telehealth scenarios).

COVID changed everything. In March 2020, the DEA waived the in-person exam requirement under public health emergency authority. That waiver has been extended multiple times and remains in effect through December 31, 2026. Right now, you can prescribe Schedule II–V controlled substances — including amphetamines and methylphenidate — via telehealth without ever seeing the patient face-to-face, as long as:

• You conduct a real-time audiovisual evaluation (video visit, not just phone or questionnaire)
• The prescription is for a legitimate medical purpose
• You’re acting within your usual professional practice
• You comply with all other federal and state prescribing laws (DEA registration, e-prescribing, PDMP checks, etc.)

This extension gives providers and patients breathing room while the DEA finalizes permanent rules. But it’s temporary — after 2026, new requirements will kick in.

What’s Coming: DEA’s Permanent Telemedicine Rules

In January 2025, the DEA announced three new rules to make some telehealth flexibilities permanent while adding patient safeguards. Key elements for ADHD prescribers:

1. Telemedicine Special Registration
The DEA is creating a special registration pathway that will allow providers to prescribe controlled substances via telehealth to new patients without an in-person exam. To qualify, you’ll likely need to:

• Obtain a DEA Telemedicine Special Registration (in addition to your standard DEA number)
• Check a nationwide PDMP database (the DEA is building a centralized hub)
• Verify patient identity during the video consult
• Follow strict documentation protocols

For established patients (those you’ve seen in person at least once), these extra requirements won’t apply — you can continue telehealth treatment freely.

2. Tiered Approach for New Patients
While final rule text isn’t published yet, the DEA has signaled a possible tiered system:

• Initial 30-day supply of Schedule II stimulants may be allowed via telehealth without special registration
• Ongoing treatment beyond 30 days would require either the telemedicine special registration or an in-person visit

This balances access with safety, though details could change before final publication (expected in 2026).

3. Platform Registration
For the first time, telehealth companies (not just individual providers) will need to register with the DEA if they facilitate controlled substance prescribing. This adds corporate-level oversight to prevent ‘pill mill’ behavior.

Bottom line: If you’re serious about telehealth ADHD care, plan to obtain the telemedicine special registration when it becomes available. It will be your ticket to continuing uninterrupted care after the current waiver expires.

Free consultations available with select providers only.

Grow your practice on Klarity

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

Start seeing patients

Free to list. Pay only for new patient bookings. Most providers see their first patient within 24 hours.

State Rules: Where It Gets Complicated

Federal law sets the floor, but states control medical licensing and scope of practice. What you can do as an ADHD telehealth provider depends heavily on where your patient is located and what type of license you hold.

Let’s break down the six key markets:

California: Permissive Rules, NP Independence Coming

Telehealth Prescribing:
California doesn’t require an in-person exam for prescribing — state law explicitly allows telehealth encounters to satisfy the ‘appropriate prior examination’ requirement. You can evaluate an ADHD patient via video and prescribe stimulants the same day, as long as the assessment meets the standard of care.

Licensure:
You must hold a California medical license (or APRN license for NPs). CA is not part of the Interstate Medical Licensure Compact, so out-of-state physicians need to complete the full licensing process. No shortcuts.

PMHNP Scope:
California is in the middle of a transition to full practice authority for nurse practitioners. As of 2023, experienced NPs (those who’ve completed 3 years or 4,600 hours under physician supervision) can apply for independent practice status. By 2026, these ‘103/104 NPs’ can practice and prescribe without physician oversight — including ADHD medications.

New grad NPs still need supervising agreements initially, but the trend is clear: California is moving toward NP autonomy, which expands the pool of available ADHD prescribers.

PDMP Requirements:
You must check California’s CURES database before prescribing any Schedule II stimulant for the first time, and at least every 4 months for ongoing treatment. Document every check.

Key Takeaway: California’s regulatory environment is telehealth-friendly for ADHD care. The main hurdle is getting licensed in the state.

Texas: Physicians Only for Stimulants

Telehealth Prescribing:
Texas allows telemedicine for mental health treatment, and there’s no state-specific ban on prescribing stimulants via telehealth. The catch? Only physicians (MD/DO) can prescribe them.

The NP Restriction:
Texas is one of the most restrictive states for nurse practitioner prescribing. APRNs and PAs cannot prescribe Schedule II controlled substances in outpatient settings — period. The only exceptions are extremely narrow: hospital inpatient orders for patients admitted ≥24 hours, hospice care, or ER emergency orders.

Outpatient ADHD treatment doesn’t qualify. If you’re an NP or PA in Texas, you cannot write prescriptions for Adderall, Ritalin, or any other Schedule II stimulant for your telehealth patients. A physician must be involved.

For Psychiatrists:
Full prescribing authority via telehealth. Texas is part of the Interstate Medical Licensure Compact, so out-of-state psychiatrists can expedite getting a Texas license if they qualify.

E-Prescribing:
Texas mandates electronic prescribing for all controlled substances. You’ll need EPCS (Electronic Prescribing of Controlled Substances) technology set up.

PDMP:
Texas requires PMP checks for opioids, benzos, barbiturates, and carisoprodol — stimulants aren’t on the mandatory list, but checking is strongly recommended as due diligence.

Key Takeaway: If you’re building an ADHD telehealth practice in Texas, it’s a physician-only game for stimulant prescribing. NPs can handle evaluation and therapy recommendations, but a psychiatrist needs to sign the prescriptions.

Florida: Clear Exception for Psychiatric Treatment

Telehealth Prescribing:
Florida explicitly allows prescribing Schedule II controlled substances via telehealth for treatment of psychiatric disorders. ADHD qualifies. This carved-out exception means you can prescribe stimulants after a video evaluation without any in-person visit, as long as it’s for mental health treatment.

Out-of-State Registration:
Florida offers a unique out-of-state telehealth provider registration system. If you’re licensed in another state, you can register with Florida’s Department of Health to provide telehealth services to Florida patients without getting a full Florida license. You’ll need to meet certain criteria (active unrestricted license elsewhere, clean disciplinary record, malpractice insurance), but once registered, you can treat Florida ADHD patients remotely — including prescribing controlled substances under the psychiatric exception.

This is a huge advantage for providers looking to expand their telehealth reach without collecting multiple full state licenses.

PMHNP Scope:
Florida requires APRNs to practice under a physician protocol. However, psychiatric nurse practitioners (PMHNPs with advanced psych training and 2+ years of supervised clinical experience) are exempt from the 7-day limit on Schedule II prescriptions that applies to other NPs. They can prescribe full-length stimulant refills.

Importantly, psych NPs must still have a written protocol with a supervising psychiatrist — Florida’s recent NP independence law excluded psychiatric APRNs. The psychiatrist doesn’t need to co-sign every prescription, but the oversight relationship must exist.

PDMP:
Mandatory check of Florida’s E-FORCSE database before prescribing controlled substances to patients age 16 or older (with limited exceptions for 3-day non-refillable supplies).

Key Takeaway: Florida’s explicit psychiatric exception makes it one of the clearest states for telehealth ADHD prescribing. The out-of-state registration option is a game-changer for multi-state telehealth providers.

New York: Recently Aligned with Federal Rules

Telehealth Prescribing:
As of May 2025, New York updated its regulations to explicitly allow prescribing controlled substances via telehealth when consistent with federal law. Previously, state rules mirrored the Ryan Haight Act’s in-person requirement. Now, as long as federal flexibilities are in place (through 2026), you can prescribe ADHD stimulants via video visits in New York.

Mandatory Compliance:
All New York prescribing rules still apply:

• I-STOP/PMP registry check required for every Schedule II, III, or IV controlled substance prescription (including stimulants)
• Electronic prescribing mandatory for all controlled substances (since 2016)
• Standard documentation and identity verification

PMHNP Scope:
New York allows experienced NPs (those with more than 3,600 hours of practice) to practice independently without a written collaborative agreement. PMHNPs can prescribe Schedule II–V controlled substances with their own DEA registration and NYS narcotic prescribing number.

There are no state-specific quantity limits for NP prescribing of stimulants — they have the same authority as physicians.

90-Day Supply Option:
Uniquely, New York allows up to a 90-day supply of stimulants for ADHD (versus the usual 30-day limit for Schedule II drugs) if the prescription is coded for ‘minimal brain dysfunction’ (old term for ADHD) or narcolepsy. Assign Code B on the prescription. This applies to both physicians and NPs and can reduce administrative burden for stable patients.

Key Takeaway: New York’s 2025 regulatory update removes state-level barriers to telehealth ADHD prescribing. The strict PDMP and e-prescribing requirements demand tight compliance, but experienced NPs have essentially the same prescribing power as psychiatrists.

Pennsylvania: Standard Telehealth, NP Collaboration Required

Telehealth Prescribing:
Pennsylvania has no state law prohibiting controlled substance prescribing via telehealth beyond federal requirements. Medical boards permit establishing patient relationships through telemedicine and prescribing if the standard of care is met. With federal flexibilities in place, PA providers can prescribe ADHD medications via video visits.

E-Prescribing:
Mandatory for controlled substances since 2019 (Act 96), with few exceptions.

PMHNP Scope:
Pennsylvania is a restricted practice state for NPs. CRNPs must have a collaborative agreement with a physician to practice and prescribe. Key limitations:

• NPs can prescribe Schedule II controlled substances for up to a 30-day supply
• Any continuation beyond 30 days requires physician approval (the collaborating doctor must be consulted, though they don’t need to see the patient)
• The physician must be available for consultation and their name on file with the state

For ADHD treatment, this means a PMHNP on your telehealth platform can write the initial month of Adderall, but needs to loop in their supervising psychiatrist before month two. Collaborative agreements often specify protocols for pediatric patients as well.

Physicians:
Full authority to prescribe. PA is part of the Interstate Medical Licensure Compact, so out-of-state psychiatrists can expedite getting licensed.

PDMP:
Required to check PA PDMP before the initial prescription of any controlled substance in a new course of treatment. While the law specifically mandates checks for opioids/benzos each time, best practice is to check for stimulants every visit as well.

Key Takeaway: Pennsylvania’s telehealth environment is friendly, but NP prescribing requires tight physician collaboration with 30-day supply limits. Document that your evaluation meets in-person standards.

Illinois: NP Independence Available, But With Conditions

Telehealth Prescribing:
Illinois permits telehealth broadly with no state-imposed barriers to controlled substance prescribing beyond federal law. The Telehealth Act (updated 2021) ensures parity and allows provider-patient relationships to be established via video.

Licensure:
Providers must hold an Illinois license plus an Illinois Controlled Substance License (separate from DEA registration). This applies to all prescribers of controlled drugs in IL — an extra administrative step but straightforward.

PMHNP Scope — Two Tiers:

Tier 1: Collaborative Practice
NPs without full practice authority must work under a written collaborative agreement with a physician. For Schedule II prescribing:

• Initial prescription limited to 30-day supply
• Any continuation beyond 30 days requires physician approval
• The collaborating physician must review the NP’s Schedule II prescribing monthly (chart review)

Tier 2: Full Practice Authority (FPA)
Illinois APRNs who complete 4,000 hours of clinical practice under supervision plus 250 hours of continuing education can apply for Full Practice Authority status. FPA APRNs can practice and prescribe independently, including controlled substances.

Here’s the critical detail: Illinois law requires FPA APRNs to have a ‘consultation relationship’ with a physician when prescribing Schedule II narcotic drugs (opioids) or benzodiazepines. However, this requirement does not apply to Schedule II non-narcotic controlled substances — which includes stimulants for ADHD.

Translation: An Illinois FPA-certified PMHNP can prescribe Adderall independently via telehealth with zero physician oversight. No monthly chart reviews, no 30-day limits, no physician consultation needed — because amphetamines are Schedule II non-narcotics.

This makes Illinois FPA NPs functionally equivalent to psychiatrists for ADHD treatment.

PDMP:
Illinois law mandates documenting PMP checks for opioids and initial benzodiazepine prescriptions. Stimulants aren’t explicitly required, but checking is recommended best practice.

Prescribing Psychologists:
Illinois allows specially trained clinical psychologists to prescribe certain psychotropic medications with physician collaboration. However, they are prohibited from prescribing Schedule II substances, which excludes stimulants. ADHD medication management remains with MD/DO, NPs, and PAs.

Key Takeaway: Illinois offers a clear path to NP independence for ADHD prescribing through FPA certification. If using non-FPA NPs, expect the same 30-day limit and physician approval requirements as Pennsylvania.

State Comparison: Quick Reference

The Economics of Telehealth ADHD Prescribing

Let’s talk business reality. Many providers consider telehealth ADHD care because they’ve heard it’s a way to build patient volume quickly. But there’s a common misconception about patient acquisition costs that needs addressing.

The DIY Marketing Math Doesn’t Add Up for Most Providers

You’ll see claims that you can acquire ADHD patients for ‘$30-50 per patient’ through SEO or Google Ads. That’s fantasy. Here’s the real picture:

SEO takes 6-12 months of consistent investment before generating meaningful patient flow. You need a content strategy, technical optimization, backlinks — and either the expertise to do it yourself or $2,000-5,000/month to hire an agency. Most solo providers don’t have the patience or budget to wait a year for results.

Google Ads for mental health keywords run $15-40+ per click. Most clicks don’t convert to booked patients. Factor in ad spend testing, optimization, landing page development, and staff time handling leads — your cost per booked patient is realistically $200-400+, not $30.

Directory listings (Psychology Today, Zocdoc) charge monthly fees ($30-200/month) plus per-booking fees ($35-100+). You’re competing with hundreds of other providers on the same page, and you still need to handle intake, insurance verification, and no-shows.

When you factor in ALL costs — agency fees, ad spend, staff time qualifying leads, no-show rates from cold leads, and failed campaigns — DIY patient acquisition typically runs $200-500+ per qualified psychiatric patient. And that’s assuming you have the marketing expertise to avoid expensive mistakes.

The Platform Alternative

This is where a pay-per-appointment model like Klarity Health makes economic sense. Instead of gambling $3,000-5,000/month on marketing with uncertain results, you pay only when a qualified patient books with you.

The value proposition:

• No upfront marketing spend — you’re not funding an ad budget or paying monthly retainers
• Pre-qualified patients already matched to your specialty (ADHD) and availability
• No wasted ad spend on clicks that don’t convert
• Built-in telehealth infrastructure — no separate platform costs for video, EHR, e-prescribing
• Both insurance and cash-pay patient flow without the credentialing headaches
• You control your schedule — scale up or down based on availability

Yes, you pay a standard listing fee per new patient lead. But compare that to spending $5,000/month on marketing that might bring 10-15 patients (if you’re lucky and know what you’re doing). With a platform model, every dollar spent brings a guaranteed patient appointment — that’s ROI you can count on.

DIY marketing can eventually be cost-effective IF you have the budget, expertise, and patience. But for most providers — especially those starting out, scaling a practice, or juggling clinical work — it removes the financial risk entirely.

Compliance Checklist: Covering Your Bases

Whether you’re prescribing through your own practice or a platform like Klarity, follow these steps to stay compliant:

Federal Requirements

• ✅ Maintain valid DEA registration covering the patient’s state
• ✅ Conduct real-time audiovisual evaluation (not just phone or questionnaire)
• ✅ Document that the prescription is for a legitimate medical purpose
• ✅ Use electronic prescribing for controlled substances (EPCS)
• ✅ Monitor for upcoming DEA telemedicine special registration requirements (likely 2027)

State-Specific Requirements

• ✅ Hold active medical/nursing license in the state where the patient is located
• ✅ Check state PDMP database before prescribing (initial and periodic):
• California: CURES (mandatory)
• Texas: TX PMP (recommended, not required for stimulants)
• Florida: E-FORCSE (mandatory)
• New York: I-STOP (mandatory every time)
• Pennsylvania: PA PDMP (mandatory initial and periodic)
• Illinois: AWARxE (recommended)
• ✅ Follow scope-of-practice limitations:
• Texas NPs: Cannot prescribe Schedule II outpatient
• PA/IL NPs (non-FPA): 30-day limit, physician approval for continuation
• FL NPs: Physician protocol required
• ✅ Document telehealth consent and patient identity verification
• ✅ Maintain records per state medical board standards

Clinical Best Practices

• ✅ Conduct thorough ADHD assessment using DSM-5 criteria
• ✅ Rule out contraindications and screen for comorbid conditions
• ✅ Review patient medication history for overlapping prescriptions
• ✅ Establish clear treatment plan with monitoring schedule
• ✅ Document rationale for stimulant selection and dosing
• ✅ Set expectations for follow-up frequency (typically monthly initially)

What’s Next: Preparing for 2027 Rule Changes

The current federal flexibility expires December 31, 2026. Here’s what to expect:

Q1-Q2 2026: DEA publishes final telemedicine prescribing rules in the Federal Register. Watch for:

• Telemedicine Special Registration application process and fees
• Nationwide PDMP integration requirements
• Identity verification standards
• Any in-person exam requirements for ongoing treatment

Q3-Q4 2026: State medical boards may issue guidance aligning with or adding to federal rules. Some states might impose stricter requirements.

January 1, 2027: New permanent rules take effect. Providers who want to continue prescribing ADHD medications via telehealth without in-person exams will need to:

• Obtain the telemedicine special registration
• Implement required PDMP checking (likely mandatory nationwide)
• Update documentation and identity verification processes
• Possibly complete specific training on telehealth controlled substance prescribing

Action Item: Don’t wait until December 2026. As soon as the DEA opens registration applications (likely mid-2026), apply immediately to avoid any gap in your ability to treat patients.

Join the Klarity Provider Network

Navigating federal and state regulations, setting up EPCS, managing PDMP checks across multiple states, and building patient volume — it’s a lot to handle solo.

Klarity Health handles the infrastructure so you can focus on patient care. Our platform:

• Matches you with pre-qualified ADHD patients in states where you’re licensed
• Manages all compliance requirements — PDMP checks, documentation standards, regulatory updates
• Provides integrated telehealth technology — video visits, EHR, e-prescribing in one system
• Handles credentialing for insurance panels (if you choose to accept insurance)
• Supports both cash-pay and insurance patients for flexible revenue streams
• Keeps you updated on regulatory changes — you’ll know about DEA rule changes before they affect your practice

You control:

• Your schedule and patient volume
• Which states you practice in (where you hold licenses)
• Your treatment approach and clinical decisions
• Your income (you set availability, we fill it)

Whether you’re a psychiatrist looking to add telehealth hours, a PMHNP building an independent practice, or an experienced clinician exploring new practice models, Klarity offers a compliant, economically smart way to grow your ADHD patient panel.

Ready to explore the platform? Visit [Klarity Health for Providers] to learn more about joining our network, compensation structure, and how we support your practice growth while keeping you compliant across all 50 states.

Frequently Asked Questions

Q: Can I prescribe ADHD medications on the first telehealth visit?
A: Yes, under current federal rules (through December 2026), you can prescribe Schedule II stimulants after an initial video evaluation without any prior in-person visit, as long as you conduct a thorough assessment and document appropriately. After 2026, you’ll likely need DEA telemedicine special registration to continue this practice.

Q: Do I need separate DEA registrations for each state?
A: Yes. Your DEA registration must cover each state where you prescribe controlled substances. If you treat patients in California, Texas, and Florida, you need DEA registrations for all three states. Each registration requires the state medical license first.

Q: What’s the difference between a psychiatrist and PMHNP for ADHD telehealth?
A: Psychiatrists (MD/DO) have full prescribing authority in all states for ADHD medications via telehealth. PMHNPs’ authority varies by state — some states grant full independence (CA, NY, IL with FPA), others require physician collaboration (PA, FL), and Texas prohibits NP prescribing of Schedule II stimulants entirely. Both can provide excellent ADHD care; the regulatory pathway differs.

Q: Can I treat pediatric ADHD patients via telehealth?
A: Yes, but ensure parent/guardian consent and involvement in the evaluation. Some states require the parent to be present during the video visit for minors. Follow the same diagnostic rigor as you would in-person, and document thoroughly. Check if your malpractice insurance covers telehealth pediatrics.

Q: What happens if I prescribe in a state where I’m not licensed?
A: That’s practicing medicine without a license — a serious legal violation that can result in disciplinary action, loss of license, and potential criminal charges. Never treat patients located in states where you don’t hold an active medical/nursing license, even if they’re your existing patients who ‘happened to travel.’

Q: How do I check PDMP databases across multiple states?
A: Most states have online PDMP portals. Some platforms (like Klarity) integrate PDMP checks into the workflow. If practicing in multiple states, you’ll need to register for each state’s PDMP system and check before prescribing. Some states participate in interstate data sharing, but it’s not universal yet. Budget 5-10 minutes per patient for PDMP review.

Q: Are there any ADHD medications I can prescribe without these restrictions?
A: Non-stimulant ADHD medications like atomoxetine (Strattera), guanfacine (Intuniv), and clonidine (Kapvay) are not controlled substances, so they don’t require PDMP checks or DEA registration. You can prescribe them via telehealth with just your state medical license. However, stimulants remain first-line treatment for many ADHD patients, so most telehealth ADHD practices need controlled substance prescribing capability.

Q: What if a patient is using multiple providers and I see overlapping stimulant prescriptions in the PDMP?
A: This is a red flag. Document it, discuss directly with the patient to understand the situation, and contact the other prescriber if appropriate. You have a duty to prevent doctor shopping and diversion. If you suspect abuse or diversion, don’t prescribe. In some states, you’re required to report concerning patterns to the medical board or PDMP authority.

Q: Can I prescribe via audio-only (phone) visits?
A: No, not for controlled substances. Federal DEA rules and most state laws require real-time audiovisual (video) communication to prescribe Schedule II stimulants via telehealth. Audio-only doesn’t meet the standard. There were temporary exceptions during early COVID for some substance use disorder meds, but those don’t extend to ADHD stimulants.

Citations and Sources

The following sources were consulted to ensure regulatory accuracy. All information reflects the latest available data as of February 2026.

1. DEA & HHS Press Release – Extension of Telemedicine Flexibilities Through 2026 (January 2, 2026)
   https://www.hhs.gov/press-room/dea-telemedicine-extension-2026.html

2. DEA Press Release – Three New Telemedicine Rules to Continue Open Access (January 16, 2025)
   https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access

3. New York State Department of Health – Guidance on Prescribing Controlled Substances via Telehealth (May 2025)
   https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth

4. Florida Statutes §456.47 – Telehealth and Controlled Substances
   https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499/0456/Sections/0456.47.html

5. Texas Board of Nursing – APRN Practice FAQ on Controlled Substance Prescribing
   https://www.bon.texas.gov/faqpracticeaprn.asp.html

6. RxAgent – NP Prescriptive Authority by State: 2026 Guide (December 28, 2025)
   https://rxagent.co/blog/np-prescribing-authority

7. Center for Connected Health Policy – State Telehealth Laws: Online Prescribing (January 2026)
   https://www.cchpca.org/topic/online-prescribing/

8. Pennsylvania Code – CRNP Prescriptive Authority Regulations (Title 49, Chapter 21)
   https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html

9. Illinois Administrative Code – Nurse Practice Act Rules (Title 68, Part 1300)
   https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300

10. Florida Statutes §464.012 – Nursing Practice Act: Prescribing Authority
    https://www.leg.state.fl.us/statutes/index.cfm?StatuteYear=2017&URL=0400-0499/0464/Sections/0464.012.html

Disclaimer: This content is for informational purposes only and does not constitute legal or medical advice. Regulations change frequently — verify current rules with your state medical board and the DEA before making practice decisions. Consult with legal counsel for specific compliance questions.

Source:

• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,II%20to%20Schedule%20V%20drugs
• https://www.healthcaredive.com/news/dea-hhs-extend-telehealth-controlled-substance-prescriptions-flexibilities-fourth-time/808735/#:~:text=,to%20hash%20out%20permanent%20regulations
• https://rxagent.co/blog/np-prescribing-authority#:~:text=Proposed%20DEA%20rules%20create%20a,for%20telemedicine%20prescribing
• https://www.leg.state.fl.us/statutes/index.cfm?Appmode=DisplayStatute&URL=0400-0499%2F0456%2FSections%2F0456.47.html#:~:text=telehealth%20to%20provide%20health%20care,in%20Schedule%20II%20of%20s
• https://www.bon.texas.gov/faqpracticeaprn.asp.html#:~:text=there%20any%20settings%20other%20than,may%20prescribe%20Schedule%20II%20controlled
• https://www.ninthdistrict.org/home/2025/05/30/nysdoh-issues-guidance-on-prescribing-controlled-substances-via-telehealth#:~:text=as%20such%20terms%20are%20defined,the%20use%20of%20electronic%20prescribing
• https://www.pacodeandbulletin.gov/secure/pacode/data/049/chapter21/chap21toc.html#:~:text=,
• https://www.ilga.gov/agencies/JCAR/EntirePart?titlepart=06801300#:~:text=match%20at%20L5536%203,collaborating%20physician%20or%20podiatric%20physician
• https://rxagent.co/blog/np-prescribing-authority#:~:text=However%2C%20,3
• https://www.cchpca.org/topic/online-prescribing/#:~:text=Prescribing%2C%20dispensing%2C%20or%20furnishing%20dangerous,the%20appropriate%20standard%20of%20care